Search research articles
Contact Us
Filters
Showing results (501-510 of 603) with videos related to
Page
of 61
Sort By:
British Journal of Haematology
|
August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
Dai Chihara, Barbara Pro, Sanam Loghavi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma
Ehsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Head & Neck
|
April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
Chelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist
|
April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
Hun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Experimental Hematology & Oncology
|
February 7, 2024
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Fangfang Yan, Vivian Jiang, Alexa Jordan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 27, 2019
Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocks
John R Hannon, Lee R Lynd, Onofre Andrade, et al.
Blood
|
June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Plos One
|
March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
Dai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
Jorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Page
of 61
Search research articles
Search
Showing results (501-510 of 603) with videos related to
Sort By:
Page
of 61
British Journal of Haematology
|
August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
Dai Chihara, Barbara Pro, Sanam Loghavi, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma
Ehsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Head & Neck
|
April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma
Chelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
The Oncologist
|
April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
Hun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Experimental Hematology & Oncology
|
February 7, 2024
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
Fangfang Yan, Vivian Jiang, Alexa Jordan, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 27, 2019
Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocks
John R Hannon, Lee R Lynd, Onofre Andrade, et al.
Blood
|
June 4, 2026
Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL
Jeremy S Abramson, Tanya Siddiqi, Leo I Gordon, et al.
Plos One
|
March 15, 2018
The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
Dai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
Jorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Page
of 61